US EditionPublished • loading... • Updated
Gilead Ends Midstage HIV Study as FDA Clinical Hold Continues
Summary by Patient Worthy
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Gilead Ends Midstage HIV Study as FDA Clinical Hold Continues
As reported on FierceBioTech, Gilead Sciences has closed one of its midstage clinical studies evaluating an experimental HIV regimen, following ongoing safety concerns that prompted U.S. regulators to intervene last year. The company confirmed that it has stopped safety follow-up and formally ended the phase 2/3 Wonders-2 trial after continued discussions with the U.S. Food […]
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
